@prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . @prefix prodotto: . unitaDiPersonaleInterno:MATRICOLA18686 pubblicazioni:autoreCNRDi prodotto:ID4770 . @prefix prodottidellaricerca: . @prefix istituto: . istituto:CDS059 prodottidellaricerca:prodotto prodotto:ID4770 . @prefix modulo: . modulo:ID2692 prodottidellaricerca:prodotto prodotto:ID4770 . @prefix rdf: . @prefix retescientifica: . prodotto:ID4770 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1101 . @prefix rdfs: . prodotto:ID4770 rdfs:label "Immunopharmacology of thymosin alpha1 and cytokine synergy. (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID4770 pubblicazioni:anno "2007-01-01T00:00:00+01:00"^^xsd:gYear . @prefix skos: . prodotto:ID4770 skos:altLabel "
Naylor P.H.a, Quadrini K.a, Garaci E.b, Rasi G.c, Hadden J.W.a (2007)
Immunopharmacology of thymosin alpha1 and cytokine synergy.
in Annals of the New York Academy of Sciences
"^^rdf:HTML ; pubblicazioni:autori "Naylor P.H.a, Quadrini K.a, Garaci E.b, Rasi G.c, Hadden J.W.a"^^xsd:string ; pubblicazioni:paginaInizio "235"^^xsd:string ; pubblicazioni:paginaFine "244"^^xsd:string ; pubblicazioni:altreInformazioni "Impact factor = 1.93"^^xsd:string ; pubblicazioni:numeroVolume "1112"^^xsd:string . @prefix ns11: . prodotto:ID4770 pubblicazioni:rivista ns11:ID372542 ; pubblicazioni:note "Epub 2007 Jun 13."^^xsd:string ; skos:note "ISI Web of Science (WOS)"^^xsd:string ; pubblicazioni:affiliazioni "a = IRX Therapeutics Inc., 1 BioScience Park Drive, Farmingdale, NY 11735, USA; \nb = University of Tor Vergata, Roma 2, Rome, Italy;\nc = CNR, Institute of Neurobiology and Molecular Medicine, Research Area of Tor Vergata, Rome,Italy"^^xsd:string ; pubblicazioni:titolo "Immunopharmacology of thymosin alpha1 and cytokine synergy."^^xsd:string ; prodottidellaricerca:abstract "Thymosin alpha1 (Talpha1) is a 28 amino acid biologically active protein cleaved from positions 2-29 of a precursor protein, prothymosin alpha. Since its discovery, Talpha1 has been administered to animals and humans in a wide variety of settings and its pharmacologic effects are to enhance cellular immunity. Talpha1 administration is highly effective in settings where irradiation, chemotherapy, tumor burden, or immune senescence have caused a reduction of T cell number and/or function. Recent in vitro studies, including the one reported here, suggest that Talpha1 may act via pathways commonly used by various cytokines. This raises the possibility that Talpha1 and cytokines may have synergistic activity through potentiation of cytokine activity by Talpha1. Improved control of tumor growth when tumor-bearing mice were treated with Talpha1 and high doses of IL-2 has been previously reported. We extended those studies with the Lewis lung carcinoma mouse model using IRX-2, a natural well-defined biologic containing multiple cytokines, in combination with Talpha1 (IRX-3). Although IRX-2 was effective alone (using doses that contain significantly less IL-2 than in most typical studies), adding Talpha1 led to significant improvement in survival of the tumor-bearing mice. Based on these observations, the immunopharmacology of Talpha1 predicts an important clinical role for Talpha1 in the restoration of cellular immune activity when used in combination with cytokines. Patients who experience immune suppression due to the presence of tumor, irradiation, and/or chemotherapy or aging of the host would most benefit from this treatment combination.\n\n" ; prodottidellaricerca:prodottoDi istituto:CDS059 , modulo:ID2692 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA18686 . ns11:ID372542 pubblicazioni:rivistaDi prodotto:ID4770 .